DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
265	脂肪萎縮症	2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00122668 (ClinicalTrials.gov)	November 2003	21/7/2005	Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients	Randomized Comparative Study Evaluating the Rate of Occurrence of a Lipoatrophy Syndrome in ARVnaive HIV-1 Infected Patients Receiving NRTI-Sparing Antiretroviral Regimen (Hippocampe - ANRS 121)	HIV Infections;HIV-Associated Lipodystrophy Syndrome	Drug: non-nucleoside reverse transcriptase inhibitors;Drug: nucleoside reverse transcriptase inhibitors;Drug: protease inhibitor	French National Agency for Research on AIDS and Viral Hepatitis	NULL	Terminated	18 Years	N/A	Both	112	Phase 4	France
2	NCT00122655 (ClinicalTrials.gov)	January 2001	21/7/2005	Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy	A Randomized Prospective Study Evaluating the Impact on Fat Distribution of NRTI-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy ANRS 108 NONUKE Study	HIV Infections;HIV Lipodystrophy Syndrome	Drug: non-nucleoside reverse transcriptase inhibitors;Drug: nucleoside reverse transcriptase inhibitors;Drug: protease inhibitors	French National Agency for Research on AIDS and Viral Hepatitis	NULL	Terminated	18 Years	N/A	Both	100	Phase 4	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00122668
(ClinicalTrials.gov)

November 2003

21/7/2005

Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients

Randomized Comparative Study Evaluating the Rate of Occurrence of a Lipoatrophy Syndrome in ARVnaive HIV-1 Infected Patients Receiving NRTI-Sparing Antiretroviral Regimen (Hippocampe - ANRS 121)

HIV Infections;HIV-Associated Lipodystrophy Syndrome

Drug: non-nucleoside reverse transcriptase inhibitors;Drug: nucleoside reverse transcriptase inhibitors;Drug: protease inhibitor

French National Agency for Research on AIDS and Viral Hepatitis

NULL

Terminated

18 Years

N/A

Both

112

Phase 4

France

NCT00122655
(ClinicalTrials.gov)

January 2001

21/7/2005

Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy

A Randomized Prospective Study Evaluating the Impact on Fat Distribution of NRTI-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy ANRS 108 NONUKE Study

HIV Infections;HIV Lipodystrophy Syndrome

Drug: non-nucleoside reverse transcriptase inhibitors;Drug: nucleoside reverse transcriptase inhibitors;Drug: protease inhibitors